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Background. Microinflammation is linked to cardiovascular
disease, and is highly prevalent in dialysis patients. It is logical
to postulate that septicemia, a common macroinflammatory oc-
currence in dialysis patients, contributes to their large burden
of cardiovascular disease.
Methods. The Dialysis Morbidity and Mortality Wave 2 was
a randomly selected prospective cohort of incident dialysis pa-
tients. Admission claims data were used to define and calculate
rates of septicemia or bacteremia and cardiovascular events in
those with Medicare as the primary payer. Utilizing Cox propor-
tional hazard models we determined the association between
baseline access and the development of bacteremia or sepsis,
and also the association between bacteremia or sepsis episodes
and subsequent cardiovascular events.
Results. The 2358 (59%) patients with Medicare as primary
payer were older and more likely to have heart failure than
those with other payers, but had similar comorbidity-adjusted
mortality hazards. Rates of first septicemia, bacteremia, or ei-
ther condition, were 7.0, 5.9 and 10.4 events per 100-patient
years, respectively. Cox regression identified initial dialysis
access as the main antecedent of septicemia or bacteremia.
Hazards ratios for hemodialysis with permanent catheters, tem-
porary catheters, and grafts were 1.95 (95% CI 1.47-2.57), 1.76
(95% CI 1.29-2.41), and 1.05 (95% CI 0.82-1.35), respectively,
while that for peritoneal dialysis was 0.96 (95% CI 0.75-1.23)
(reference arteriovenous fistula). After adjustment for baseline
factors, septicemia or bacteremia, as a time-dependent covari-
ate, was associated with subsequent death [hazards ratio (HR)
2.33, 95% CI 1.38-2.28], myocardial infarction (HR 1.78, 95% CI
1.38-2.28), heart failure (HR 1.64, 95% CI 1.39-1.95), peripheral
1The data reported here have been supplied by the United States Renal
Data System (USRDS). The interpretation and reporting of these data
are the responsibility of the authors and in no way should be seen as an
official policy or interpretation of the United States government
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vascular disease (HR 1.64, 95% CI 1.34-2.0), and stroke (HR
2.04, 95% CI 1.27-3.28).
Conclusion. Septicemia appears to be an important, poten-
tially preventable, cardiovascular risk factor in dialysis patients.
Atherosclerosis and microinflammation are interre-
lated [1]. Infection is a classic macroinflammatory state
and it is logical to postulate that infection may underpin
the lethal synergy between inflammation and atheroscle-
rosis. Cardiovascular disease is highly prevalent in those
initiating dialysis. Dialysis patients have an excess of car-
diovascular mortality that is poorly explained by tradi-
tional cardiovascular risk factors [2–4]. As in the general
population, inflammatory markers have been demon-
strated to be independent predictors of cardiovascular
outcomes in hemodialysis [5] and peritoneal patients [6].
Access for dialysis is a significant source of infection
and morbidity in those undergoing both hemodialysis
and peritoneal dialysis [7–9]. It is unknown whether bac-
teremia or septicemia, clinical markers for a macroin-
flammatory state, has the same adverse association with
cardiovascular disease as microinflammation.
We hypothesized that vascular access for dialysis is a
source of infection for dialysis patients, leading to inflam-
mation and cardiovascular disease. We aimed to deter-
mine rates of bacteremia or sepsis in incident dialysis
patients and to quantify the associations between (1) ac-
cess type and hospitalization for septicemia or bacteremia
and (2) septicemia or bacteremia, cardiovascular events,
and death.
METHODS
In temporal sequence, the objectives of the study were
to determine, in incident dialysis patients: (1) hospital-
ized septicemia rates (referred to as “septicemia”), (2)
bacteremia rates, not associated with hospitalization (re-
ferred to as “bacteremia”), (3) dialysis access type at
dialysis inception and subsequent associations with sep-
ticemia or bacteremia, and (4) The association between
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septicemia and/or bacteremia and subsequent cardiovas-
cular events and death.
Subjects
The Wave 2, Dialysis Morbidity and Mortality Study
(DMMS), was a prospective study, including all incident
peritoneal dialysis in the United States and one fifth
of incident hemodialysis patients, during the years 1996
and 1997. Trained individuals recorded information on
demographics, clinical variables (including access type),
comorbidities, laboratory variables, and medication use
through patient interviews and chart abstraction [10].
Dialysis access in use at study initiation was divided into
five categories, peritoneal dialysis and the following four
categories in hemodialysis patients: native fistula, graft
[polytetrafluoroethylene (PTFE) or bovine], permanent
catheter (tunneled), temporary catheter (nontunneled),
and “other” type of access. To be included in the final
analysis an individual was required to have complete
baseline data, a valid United States Renal Data System
(USRDS) identifier, and have Medicare as their primary
payer source defined as: A threshold of Medicare claims
submission totaling $675 or more in any of the 3 months
after study initiation [11]. Individuals with dialysis claims
less than this threshold amount are thought to have Medi-
care as a supplemental payer and consequently prone to
misclassification bias as many events [International Clas-
sification of Diseases, Ninth Revision (ICD-9 codes of
interest)] would be missed by a Medicare only claims
search. Blood pressure values utilized in all analyses were
the mean of the last three clinically recorded blood pres-
sures prior to the initiation of the study.
Outcomes
The participants of the Wave 2 Study were linked elec-
tronically to the USRDS through the use of a unique
identifier to obtain subsequent Medicare claims and vi-
tal status. Claims data were available until December
31, 1999. With the exception of death, all outcomes in
this study were obtained from Medicare claims data.
Providers and facilities submit Medicare claims at the
time of service and document, through the use of ICD-9
codes, the reason for the claim.
Outcomes were defined with the following Interna-
tional Classification of Disease, Ninth Revision, Clinical
Modification (ICD-9-CM) codes: (1) septicemia: codes
038.xx, where x is from 0 to 9 inclusive; streptococcal
(038.0x), staphylococcal (038.1x), pneumococcal (038.2),
anaerobic (038.3), aerobic gram-negative (038.4x), other
specified septicemia (038.8) and unspecified septicemia
(038.9) are defined by these terms; (2) bacteremia: code
790.7, defined as bacterial infection with no signs of in-
fection; (3) myocardial infarction: codes 410.xx (except
410.x2); (4) congestive heart failure: codes 402.x1, 425.xx,
428.xx, 518.4, and 398.91; (5) stroke: codes 430.xx, 431.xx,
432.xx, 433.xx, 434.xx; and (6) peripheral vascular disease:
codes 440.xx to 444.xx (except 443.0) and 447.xx (except
447.0, 447.6, 447.8, and 447.9).
Follow-up
Follow-up began at the study start-date, which was
60 days after the first dialysis treatment. The follow-up
time for each event was defined as the time from initi-
ation of the study until the date of the index event, the
date of death, the date at which an individual was deemed
lost to follow-up (defined as Medicare claims for dialysis
below the threshold value of $675 in any 3-month pe-
riod between study initiation and study end), or at the
completion of the study, December 31, 1999. Individuals
were considered censored if they were lost to follow-up
or upon completion of the study without an index event.
Deaths were ascertained through the end-stage renal dis-
ease (ESRD) death notification form (CMS-2746).
Analysis
To determine the effect of excluding non-Medicare re-
cipients from our analyses we compared baseline data
and survival in those with and without Medicare as
their primary payer. Patients with and without Medi-
care as primary payer were compared using t tests for
continuous parameters and v 2 analysis for proportions.
Multivariate logistic regression was used, with Medicare
as payer (yes/no) as the dependent variable and baseline
patient characteristics as exploratory variables. Finally,
the mortality hazards of patients with and without Medi-
care were compared using Cox regression, with adjust-
ment for baseline characteristics.
In those with Medicare as primary payer, standard Cox
regression was used to identify baseline covariates as-
sociated with septicemia or bacteremia, while actuarial
survival analysis was used to calculate subsequent cumu-
lative survival rates. Time-dependent Cox regression was
used to quantify the association between septicemia or
bacteremia and cardiovascular events. No screening was
performed prior to a variable being entered into the fi-
nal model. Reported P values are based on two-sided
tests and were considered significant with a ≤ 0.05. All
analyses were performed using the SAS system for Win-
dows, version 8.02 (SAS Institute, Cary, NC, USA). The
Hennepin County Medical Center Human Subjects Re-
search Committee approved this study.
RESULTS
The Wave 2 Study included 4024 individuals, of these 94
were excluded as they lacked a valid USRDS identifier.
As all of our outcomes utilized Medicare billing data we
excluded 1572 individuals from our final analysis (leaving
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Table 1. Baseline characteristic of those with and without Medicare as primary payer
Medicare primary payer
No Yes Odds ratio
(N = 1572) (N = 2358) P valuea (95% CI)b P valueb
Dialysis access% <0.0001
Temporary catheter 5.5 6.5 0.94 (0.65-1.37) 0.8
Permanent catheter 6.6 11.1 1.16 (0.83-1.64) 0.4
Graft 19.5 27.4 0.95 (0.71-1.26) 0.7
Fistula 7.5 9.9 1.0 Ref Ref
Peritoneal dialysis catheter 60.8 45.0 0.63 (0.49-0.82) 0.0006
Baseline comorbidities%
Myocardial Infarction 17.4 22.8 <0.0001 1.00 (0.82-1.22) 1.0
Congestive heart failure 31.9 44.9 <0.0001 1.16 (0.99-1.37) 0.06
Cerebrovascular accident 12.8 16.8 0.0006 1.11 (0.90-1.37) 0.3
Peripheral vascular disease 20.3 25.5 0.0001 0.93 (0.77-1.12) 0.4
Diabetes mellitus 48.6 54.0 0.001 1.16(0.89-1.54) 0.3
Primary renal disease% <0.0001
Diabetes mellitus 41.4 44.1 0.92 (0.68-1.24) 0.6
Hypertension 23.2 27.6 1.08 (0.88-1.33) 0.5
Glomerulonephritis 10.8 6.8 0.83 (0.63-1.10) 0.2
Other/unknown 24.6 21.5 1.0 Ref Ref
Age years (SD) 52.6 (14.4) 62.5 (15.5) <0.0001 1.04 (1.03-1.04) <0.0001
Race% 0.001
White 58.8 64.2 0.93 (0.72-1.21) 0.6
Black 30.7 27.8 0.88 (0.66-1.16) 0.4
Gender%
Male 50.8 53.1 0.2 1.09 (0.94-1.25) 0.2
Blood pressure mm Hg
Systolic 146.2 (20.4) 147.2 (21.7) 0.1 1.00 (1.00-1.01) 0.2
Diastolic 81.9 (12.0) 78.0 (12.1) <0.0001 0.99 (0.98-1.00) 0.07
Serum albumin (<3.0 mg/dL)% 26.7 24.1 0.03 0.99 (0.84-1.16) 0.9
Adjusted mortality hazards ratioc (95% CI) 1c (Ref) 1.11c (0.996-1.23) 0.06c
aContinuous parameters are compared using a t test. Categoric parameters are compared using the v 2 test.
bUsing logistic regression, with the presence (coded 1) or absence (coded 0) of Medicare as payer as dependent variable, with all the baseline parameters shown in
the first column as exploratory variables.
cUsing a Cox regression model, including Medicare as payer, with adjustment for all the baseline parameters shown in the first column.
N = 2358), as they had not generated sufficient dollar
value claims to the Medicare system for dialysis within 3
months of initiation of the Wave 2 Study. Additionally,
47 individuals were excluded because baseline covariate
information was missing. The final sample size included
2311, 57% of the original Wave 2 cohort.
Table 1 compares the baseline characteristics of those
with and without Medicare as primary payer. On multi-
variate analysis, patients with Medicare as primary payer
were older, and less likely to use peritoneal dialysis.
Table 1 also shows that there was a trend toward higher
adjusted mortality hazards in patients with Medicare as
primary payer.
Further outcome analysis was restricted to those with
Medicare as primary payer. The median follow-up was
3.2 years. A total of 527 patients had a first hospital-
associated episode of septicemia, 446 had a first episode
of bacteremia not associated with hospitalization, and
791 patients had at least one of the two events, yielding
an incidence of 7.0, 5.9, and 10.4 events per 100 patient
years, respectively (Fig. 1). Table 2 shows associations
between baseline characteristics of patients who either
did or did not experience septicemia or bacteremia. Cox
regression identified initial dialysis access as the main an-





































Fig. 1. Cumulative incidence of bacteremia or septicemia over time in
the Wave 2 population.
septicemia or bacteremia. Using arteriovenous fistula as
reference category, hazards ratios (HRs) for hemodial-
ysis with permanent catheters, temporary catheters, and
grafts and were 1.95 (95% CI 1.47-2.57) (P = 0.0004),
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Table 2. Baseline characteristics associated with development of septicemia or bacteremia
Bacteremia or hospitalized septicemia
Noa Yesa HRb
(N = 1533) (N = 778) P valuea (N = 2311)c 95% CIb P valueb
Dialysis access% <0.0001
Temporary catheter 5.1 9.3 1.76 1.29-2.41 0.0004
Permanent catheter 9.3 15.2 1.95 1.47-2.57 <0.0001
Graft 27.6 27.0 1.05 0.82-1.35 0.2
Fistula 10.5 8.5 1 Ref Ref
Peritoneal dialysis catheter 44.9 37.2 0.96 0.75-1.23 0.8
Comorbidities%
Myocardial infarction 23.2 21.9 0.5 0.99 0.82-1.19 0.9
Congestive heart failure 44.9 44.3 0.8 1.11 0.95-1.29 0.2
Cerebrovascular accident 16.2 17.9 0.3 1.06 0.87-1.28 0.6
Peripheral vascular disease 25.2 25.7 0.8 1.13 0.95-1.35 0.2
Diabetes mellitus 52.4 56.6 0.06 1.13 0.88-1.45 0.3
Primary renal disease% 0.6
Diabetes mellitus 43.4 45.9 0.94 0.72-1.24 0.7
Hypertension 28.2 27.0 0.89 0.72-1.10 0.3
Glomerulonephritis 7.2 6.2 0.78 0.56-1.08 0.1
Other/unknown 21.1 21.0 1.0 Ref Ref
Age years (SD) 63.1 (15.4) 61.3 (15.4) 0.01 1.00 0.97-1.01 0.7
Race% 0.0001
White 66.9 59.8 1.14 0.85-1.52 0.4
Black 25.1 33.6 1.46 1.08-1.97 0.01
Other 8.0 6.7 1
Male gender% 53.9 52.1 0.4 .96 0.84-1.11 0.6
Blood pressure mm Hg
Systolic 146.8 (21.7) 148 (21.7) 0.2 1.00 0.99-1.00 0.08
Diastolic 77.6 (12.3) 78.8 (11.8) 0.03 1.00 1.00-1.01 0.4
Serum albumin (<3.0 mg/dL)% 23.0 25.3 0.2 1.20 1.01-1.41 0.03
aContinuous parameters are compared using a t test. Categoric parameters are compared using the v 2 test.
bUsing a Cox proportional hazards model with the time to developing a bacteremia or hospitalized septicemia episode as the dependent variable, with all the baseline
parameters shown in the first column as covariates. The reference categories for categoric variables are dialysis access (fistula), absence of all comorbidities, primary
renal disease (other/unknown), race (other), and gender (female).
cA total of 47 (2.0%) Medicare patients were excluded because of missing baseline data or absence of a follow-up interval greater than zero.
1.76 (95% CI 1.29-2.41) (P < 0.0001), and 1.05 (95% CI
0.82-1.35) (P = 0.2), respectively, while that for peritoneal
dialysis was 0.96 (95% CI 0.75-1.23) (P = .8). Other sig-
nificant associations included black race and low serum
albumin (Table 2).
The occurrence of septicemia or bacteremia was as-
sociated with subsequent cardiovascular morbidity and
mortality. Figure 2 shows adjusted survival estimates af-
ter septicemia and bacteremia, with survival after my-
ocardial infarction, in the Wave 2 population, shown for
comparison. One-year adjusted survival estimates after
hospitalized septicemia, bacteremia, and myocardial in-
farction are demonstrated in Figure 2. Table 3 shows
comorbidity-adjusted HRs for death and admission for
cardiovascular events, with the first episode of septicemia
or bacteremia treated as a time-dependent covariate. The
occurrence of septicemia or bacteremia were associated
with death (HR 2.33, 95% CI 2.08-2.61) (P < 0.0001),
congestive heart failure (HR 1.65, 95% CI 1.39-1.95)
(P < 0.0001), myocardial infarction (HR 1.78, 95%CI
1.38-2.28) (P < 0.0001), peripheral vascular disease (HR
1.64, 95% CI 1.34-2.00, P < 0.0001), and stroke (HR






















Fig. 2. Actuarial adjusted survival estimates after a diagnosis of bac-
teremia, septicemia, either septicemia or bacteremia and myocardial in-
farction in the Wave 2 population. Adjusted for the following variables:
history of myocardial infarction, congestive heart failure, cerebrovas-
cular accident, peripheral vascular disease, and diabetes, primary cause
of kidney disease (diabetes, hypertension, glomerulonephritis, other),
age, race (black, white, other), mean predialysis systolic and diastolic
blood pressure, and an albumin <3.0 mg/dL).
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Table 3. Cox proportional hazards demonstrating association between bacteremia or sepsis and various outcomes with adjustment for all the
baseline variables shown in the first column
Mortality CHF events MI events PVD events CVA events
Variable HR 95% HR CI HR 95% HR CI HR 95% HR CI HR 95% HR CI HR 95% HR CL
Time to bacteremia or sepsis days 2.33 2.08-2.61 1.65 1.39-1.95 1.78 1.38-2.28 1.64 1.34-2.00 2.04 1.27-3.28
Age years 1.03 1.02-1.03 1.01 1.01-1.02 1.00 0.99-1.01 1.00 1.00-1.01 0.99 0.97-1.01
Race
White 1.49 1.19-1.87 1.44 1.10-1.88 1.32 0.86-2.02 1.40 1.01-1.93 1.62 0.64-4.11
Black 1.29 1.02-1.64 1.14 0.85-1.51 1.06 0.67-1.67 1.22 0.87-1.72 1.75 0.68-4.52
Gender, male% 1.02 0.92-1.14 1.01 0.88-1.15 1.21 0.97-1.50 1.12 0.95-1.31 1.27 0.82-1.96
Mean blood pressure
Systolic mm Hg 0.99 0.99-1.00 1.00 1.00-1.00 1.01 1.00-1.02 1.00 1.00-1.01 1.00 0.99-1.02
Diastolic mm Hg 0.99 0.99-1.00 1.00 0.99-1.00 0.99 0.97-1.00 0.99 0.98-1.00 1.01 0.98-1.04
Low albumin (<3.0 mg/dL)% 1.20 1.07-1.36 1.12 0.96-1.31 0.96 0.74-1.24 0.96 0.80-1.16 0.80 0.46-1.39
Peritoneal dialysis% 1.23 1.10-1.37 0.88 0.77-1.01 1.40 1.12-1.76 1.88 1.59-2.22 0.66 0.41-1.07
Baseline comorbidities%
Myocardial infarction 1.02 0.90-1.16 1.28 1.10-1.49 1.27 0.98-1.64 1.06 0.87-1.29 1.03 0.57-1.85
Congestive heart failure 1.19 1.07-1.33 1.75 1.52-2.01 1.37 1.09-1.73 1.22 1.03-1.45 1.14 0.72-1.82
Cerebrovascular accident 1.26 1.10-1.44 0.86 0.72-1.03 1.16 0.88-1.54 0.91 0.73-1.13 0.67 0.33-1.36
Peripheral vascular disease 1.16 1.02-1.30 1.13 0.97-1.31 1.12 0.87-1.44 1.67 1.40-2.01 0.69 0.37–1.26
Diabetes 0.90 0.75-1.09 1.02 0.81-1.28 1.16 0.79-1.68 1.29 0.98-1.71 1.25 0.62-2.54
Primary cause of renal disease%
Diabetes 1.27 1.04-1.56 1.34 1.03-1.73 1.05 0.70-1.59 1.08 0.79-1.46 0.65 0.30-1.42
Hypertension 0.87 0.74-1.02 1.10 0.90-1.34 0.88 0.63-1.23 0.93 0.73-1.20 0.59 0.32-1.09
Glomerulonephritis 0.57 0.43-0.75 0.99 0.73-1.36 0.63 0.36-1.11 0.85 0.58-1.24 0.78 0.34-1.83
Other/unknown 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Abbreviations are: HR, hazards ratio; CI, confidence interval; CL, confidence limits; CHF, congestive heart failure; MI, myocardial infarction; PVD, peripheral
vascular disease; CVA, cerebrovascular accidents.
bacteremia or sepsis on subsequent death, or cardiovas-
cular events differed by the presence or absence of car-
diovascular disease (presence of either a history of my-
ocardial infarction, congestive heart failure, peripheral
vascular disease, or cerebrovascular accident) at baseline
(Table 4). Individuals without a history of cardiovascular
disease who developed bacteremia or sepsis were more
likely to have a subsequent death or cardiovascular dis-
ease event as compared to those with a previous cardio-
vascular disease history (P < 0.0001 for the interaction).
DISCUSSION
We found that septicemia and bacteremia were com-
mon events after starting dialysis therapy and that
catheter use for hemodialysis access was the most obvi-
ous antecedent association. Also we have demonstrated
that an episode of either bacteremia or hospitalized sep-
ticemia was a harbinger of future cardiovascular events
and death especially in those without a previous history
of cardiovascular disease.
Infection is the second leading cause of death in dialy-
sis patients. Death rates from septicemia have been esti-
mated to be between 100 and 300-fold higher than in the
general population [12–14]. Some retrospective studies
have demonstrated lower rates of catheter infection than
what we are reporting [15, 16]. These lower infection rates
may have been the results of meticulous catheter care,
similar to care provided to a peritoneal dialysis catheter
and are not associated with increased mortality [17]. Al-
ternatively several other studies have shown that sep-
ticemia rates are high in dialysis populations, that the
presence of dialysis catheters, and grafts are dominant as-
sociations, and that septicemia is associated with higher
than expected mortality rates [7, 18–25]. It has been hy-
pothesized that this increased risk stems from generalized
immunosuppression of dialysis patients, interruption of
the skin barrier, and the increased age of those undergo-
ing dialysis. Other studies have demonstrated that use of
catheters as vascular access was a significant predictor of
both all-cause mortality and infection-specific mortality
[7, 26, 27]. Our study suggests that cardiovascular dis-
ease may be an intermediate stage in this process. Stated
differently, it suggests that septicemia plays a role in the
excessive burden of cardiovascular disease in dialysis pa-
tients. This phenomenon has recently been demonstrated
in the general population where Smeeth et al [28] showed
that an acute infection episode was associated with an
increased short term risk of myocardial infarctions and
stroke.
The mechanism by which septicemia and bacteremia
could lead to cardiovascular disease is not fully under-
stood. The full-blown sepsis syndrome has significant
effects on endothelial function, as well as the coagu-
lation and redox systems and overall cardiac function
[29]. We found that bacteremic episodes, not admitted
to hospital, were also associated with poor outcomes
(Fig. 3). It is tempting to speculate that bacteremic
episodes elicit an inflammatory response, which predis-
poses to overt cardiovascular dysfunction. Transmission
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Fig. 3. Hazards ratios for death, hospitalized congestive heart failure
(CHF), myocardial infarction (MI), peripheral vascular disease (PVD)
and cerebrovascular accident (CVA). The results are reported for the
occurrence of bacteremia or septicemia (b or s), bacteremia alone (b),
or septicemia alone (s). In each model the outcome of interest was
modeled as a time-dependent covariate, with adjustment for baseline
dialysis access, comorbidities, primary renal disease, age, race, gender,
systolic blood pressure, diastolic blood pressure, and serum albumin.
and scanning electron microscopy studies have demon-
strated that almost all indwelling catheters are colonized
with microorganisms, even when culture negative [30].
These organisms survive in a biofilm, and appear to be
metabolically active and viable [31]. Skin organisms mi-
grate from the catheter insertion site and colonize the ex-
ternal surface of the catheter. Pathogens, even when sub-
clinical, can induce a host inflammatory response [32]. In-
flammation has been linked to the future development of
cardiovascular disease [33]. In addition, cohort studies in
the general population suggest a dose response relation-
ship between the number of previous pathogen exposures
and the current inflammatory burden [34]. Both inflam-
mation and the previous cumulative infectious exposure
are significant predictors of atherosclerosis extent [35],
myocardial infarction, and all-cause cardiovascular mor-
bidity and mortality [36–38]. In those undergoing dialysis,
markers of inflammation are elevated eightfold to ten-
fold compared with healthy controls [5, 39]. It is possible
that the use of a catheter is associated with a subclinical
infectious state, with resulting increases in serum inflam-
matory markers, and a more rapid rate of atherosclerosis
progression. These changes are subsequently associated
with an increased cardiovascular morbidity and mortal-
ity rate. This hypothesis is supported by a recent study by
Lok et al [40], who showed, in a randomized controlled
trial, that prophylactic treatment of dialysis catheter exit
sites with polysporin ointment reduced the risk of bac-
teremia events and all-cause mortality.
Our study has several limitations. First, many individ-
uals from the original study cohort are excluded from
the current analysis, limiting the generalizability of this
study. Also, we have performed a secondary analysis of
an existing data set that was not originally designed to
address this specific issue as such, there may be other
unknown, or unmeasured factors that may explain the
association we have demonstrated between septicemia
and cardiovascular disease such as biocompatibility of
dialyzers membranes and purity of dialysate which may
independently lead to an enhanced inflammatory state
[41, 42]. Additionally, our study only included individu-
als undergoing dialysis therapy in the United States, the
applicability of these results to areas outside of the United
States is unknown, as the recent Dialysis Outcomes and
Practice Patterns (DOPP) Study demonstrated that the
percentage of dialysis initiations with a catheter are sig-
nificantly lower outside of the United States [43]. The un-
derlying condition resulting in the coding of a septicemia
event is an important issue. While the clinical definition
of septicemia is well defined, the definition of septicemia
from Medicare ICD-9 codes is unclear, but likely repre-
sents a spectrum of disease from true septicemia to bac-
teremia. The ICD-9 codes utilized are likely to be specific
for infection, but not very sensitive [44, 45]. Also, they
are poor markers for the severity of underlying disease.
It is quite possible that serious medical conditions lead to
admission, which were followed by septicemia. As such,
some of the associations between septicemia and bad out-
comes could represent an innocent bystander effect. It is
interesting that estimates of hospitalized septicemia in
this study were quite similar to those reported from the
HEMO Study, where outcomes were classified by a com-
mittee [46]. Finally, we found an association between the
baseline vascular access and subsequent hospitalizations
for septicemia. Vascular access in hemodialysis patients
changes over time and many of those classified as uti-
lizing a given access may have changed to a different
form of access through the course of the study. The Wave
2 Study categorized initial dialysis access; the associa-
tions between time-integrated access status, septicemia,
cardiovascular events, and death could not be assessed.
Regarding initial dialysis access, it is plausible that
hemodialysis catheters account for a smaller proportion
of overall follow-up, in a given patient, than fistulas or
grafts, so that the HRs presented here may be an under-
estimate of the real association.
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Table 4. Cox proportional hazards demonstrating association between bacteremia or sepsis and various outcomes with adjustment for all the
baseline variables stratified by a history of cardiovascular disease (CVD) [congestive heart failure (CHF), myocardial infarction (MI), peripheral
vascular disease (PVD), or cerebrovascular accidents (CVA)] at baseline
Mortality CHF events MI events PVD events CVA events
Variable HR 95% HR CI HR 95% HR CI HR 95% HR CI HR 95% HR CI HR 95% HR CL
No Previous CVD (N = 876) 3.48 2.82-4.29 2.25 1.69-3.00 0.3.31 2.15-5.10 1.75 1.23-2.51 2.58 1.33-5.02
Time to bacteremia or sepsis days
Previous CVD (N = 1435)
Time to bacteremia or sepsis days 2.03 1.77-2.32 1.49 1.21-1.84 1.36 0.99-1.85 1.66 1.31-2.11 1.84 0.92-3.66
CONCLUSION
We found that hemodialysis catheter use was highly
prevalent in United States dialysis patients and strongly
associated with septicemia; septicemia, in turn was as-
sociated with cardiovascular morbidity and mortality. If
this sequence of events is true, strategies leading to max-
imizing the use of arteriovenous fistula as hemodialysis
access could lower infection risk, and ultimately lower
cardiovascular event rates. When catheter use is unavoid-
able, other approaches show potential. To date, topi-
cal mupirocin, Staphylococcus aureus–conjugate vaccine,
and topical antibiotic solutions have been shown to lower
bacteremia rates in hemodialysis patients using catheters
[47–49].
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